CD274 and non-small cell lung carcinoma: These results were reinforced at ASCO 2025, where a prospective multi-center study confirmed that a four-miRNA plasma panel—including miR-155, miR-146a, miR-21, and miR-126—predicts response to anti-PD-1/PD-L1 therapy across 200 patients with melanoma, NSCLC, and renal cell carcinoma, with an area under the receiver operating characteristic curve of 0.87 for distinguishing responders from non-responders [196].